Document is current
Any future updates will be listed below
-
Authors
van Lieshout, Rianne http://orcid.org/0000-0002-1456-7820
Tick, Lidwine W.
Beckers, Erik A. M.
Biesbroek, Willemijn
Dieleman, Jeanne P.
Dijkstra, Myrthe
Groenesteijn, Wanda
Koene, Harry R.
Kranenburg, Suzanne
van der Lee, Debbie
van der Put - van den Berg, Liesbeth
Rademakers, Nicky
Regelink, Josien C.
van Tilborg, Claudia J.
Westerweel, Peter E.
de Zeeuw, Sandra
Schouten, Harry C.
Beijer, Sandra
- License Information
-
More Information
Article History
Received: 21 December 2023
Revised: 30 July 2024
Accepted: 30 July 2024
First Online: 10 August 2024
Competing interests
: RvL has received unrestricted research grants from the Vrienden Integrale Oncologische Zorg Foundation, Utrecht, The Netherlands, Baxter B.V. Utrecht, The Netherlands (Grand reference number: GHOL6759) (Category 1), and Fresenius Kabi Nederland B.V., Huis ter Heide, The Netherlands (Category 1). C.J.v.T., S.d.Z. and P.E.W. have received an unrestricted research grant from the Albert Schweitzer Hospital’s Research Fund, Dordrecht, The Netherlands. The other authors have nothing to disclose.
: The study protocol was reviewed and exempted from ethics approval by the Medical Ethics Committee Maxima MC (N17025). The study procedures were in accordance with the rules of the European Personal Data Protection Act and the Code of Ethics of the World Medical Association (Helsinki Declaration). The study was registered at The Dutch Trial Register (NTR) with trial number NL8505. Written informed consent was obtained from all patients prior to enrollment in the study.
